Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD
Status:
Active, not recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
The study aims to test if combination of quizartinib (AC220) and omacetaxine mepesuccinate
(OM, also known as homoharringtonine) results in durable composite complete remission (CRc)
in patients with newly diagnosed or relapsed/refractory (R/R) acute myeloid leukemia (AML)
carrying FLT3-ITD (Fms-Like Tyrosine Kinase 3 - Internal Tandem Duplication).